title: Decitabine studies in chronic and acute myelogenous leukemia.
authors.affiliation: MD Anderson Cancer Center, Department of Hematology, Houston, Texas 77030, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: S M
authors.initials: SM
authors.lastname: O'Brien
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: M
authors.initials: M
authors.lastname: Beran
authors.forename: M B
authors.initials: MB
authors.lastname: Rios
authors.forename: M
authors.initials: M
authors.lastname: Keating
authors.forename: D
authors.initials: D
authors.lastname: de Vos
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D000077209:Decitabine; D005260:Female; D005334:Fever; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine